Evidence map›Paper›PMID 33431934›Full record

ArticleScientific reports2021

Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks.

Zuzana Mikulkova, Gayane Manukyan, Peter Turcsanyi, Milos Kudelka, Renata Urbanova, Jakub Savara, Eliska Ochodkova, Yvona Brychtova, Jan Molinsky, Martin Simkovic and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Zuzana MikulkovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
Gayane ManukyanDepartment of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
Peter TurcsanyiDepartment of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Milos KudelkaDepartment of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
Renata UrbanovaDepartment of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Jakub SavaraDepartment of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
Eliska OchodkovaDepartment of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
Yvona BrychtovaDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic.
Jan Molinsky1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Praha, Czech Republic.
Martin SimkovicDepartment of Internal Medicine - Hematology, University Hospital and Medical School Hradec Kralove, Hradec Kralove, Czech Republic.
David StarostkaDepartment of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Jan NovakDepartment of Internal Medicine - Hematology, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Praha, Czech Republic.
Ondrej JancaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
Martin DihelDepartment of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
Pavlina RyznerovaDepartment of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Lekaa MohammadDepartment of Hematology and Oncology, University Hospital Plzen, Plzen, Czech Republic.
Tomas PapajikDepartment of Hematology-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Eva KriegovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic. eva.kriegova@email.cz.
Palacký University Olomouc · CZUniversity Hospital Olomouc · CZVSB - Technical University of Ostrava · CZCharles University · CZUniversity Hospital Brno · CZUniversity Hospital Hradec Králové · CZUniversity Hospital Plzen · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tissue microenvironment in chronic lymphocytic leukaemia (CLL) plays a key role in the pathogenesis of CLL, but the complex blood microenvironment in CLL has not yet been fully characterised. Therefore, immunophenotyping of circulating immune cells in 244 CLL patients and 52 healthy controls was performed using flow cytometry and analysed by multivariate Patient Similarity Networks (PSNs). Our study revealed high inter-individual heterogeneity in the distribution and activation of bystander immune cells in CLL, depending on the bulk of the CLL cells. High CLL counts were associated with low activation on circulating monocytes and T cells and vice versa. The highest activation of immune cells, particularly of intermediate and non-classical monocytes, was evident in patients treated with novel agents. PSNs revealed a low activation of immune cells in CLL progression, irrespective of IgHV status, Binet stage and TP53 disruption. Patients with high intermediate monocytes (> 5.4%) with low activation were 2.5 times more likely (95% confidence interval 1.421-4.403, P = 0.002) to had shorter time-to-treatment than those with low monocyte counts. Our study demonstrated the association between the activation of circulating immune cells and the bulk of CLL cells. The highest activation of bystander immune cells was detected in patients with slow disease course and in those treated with novel agents. The subset of intermediate monocytes showed predictive value for time-to-treatment in CLL.

Indexed as

AdultAgedFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedModels, BiologicalTumor Microenvironment

Identifiers

PMID33431934
PMCPMC7801466
OpenAlexW3120988861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.